Le Lézard
Classified in: Health
Subject: MRR

Influenza Vaccine Market size is set to grow by USD 2.93 billion from 2023-2027, increasing prevalence and incidence of influenza boost the market, Technavio

NEW YORK, April 16, 2024 /PRNewswire/ -- The global influenza vaccine market  size is estimated to grow by USD 2933.88 mn from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of  6.89%  during the forecast period.  The global influenza vaccine market is experiencing growth due to rising influenza cases and hospitalizations, particularly in the US. According to CDC data, 39-56 million people had flu from Oct 2019 to Mar 2020, leading to 400,000-730,000 hospitalizations. Severe cases, children, and regional epidemics are driving demand for influenza vaccines, including combination, mRNA, swine flu, and inactivated types. Vaccines are available at hospitals & pharmacies, and include quadrivalent, adult, and pediatric options. Influenza viruses continually evolve, requiring updated vaccine strains for seasonal influenza vaccines. 

For more insights on the historic (2017 - 2021) and forecast market sizeRequest a sample report

Influenza Vaccine Market Scope

Report Coverage


Base year


Historic period

2017 - 2021

Forecast period


Growth momentum & CAGR

Accelerate at a CAGR of 6.89%

Market growth 2023-2027

USD 2933.88 million

Market structure


YoY growth 2022-2023 (%)


Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 54%

Key countries

US, Canada, UK, China, and India

Key companies profiled

Altimmune Inc., AstraZeneca PLC, Baxter International Inc., BioDiem Ltd, BiondVax Pharmaceuticals Ltd., CSL Ltd., Emergent BioSolutions Inc., F. Hoffmann La Roche Ltd., FluGen Inc., GlaxoSmithKline Plc, Mitsubishi Chemical Group Corp., Novavax Inc., Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi SA, Shijiazhuang Yiling Pharmaceutical Co Ltd., SK Chemicals Co. Ltd., Vaccitech Plc, Vaxart Inc., and Vaxine Pty Ltd.

Segment Overview 

This influenza vaccine market report extensively covers market segmentation by Distribution Channel (Hospitals and pharmacies, Government and institutional, Others) Type (Live attenuated influenza vaccines, Recombinant influenza vaccines) Geography (North America, Europe, Asia, Rest of World (ROW))

Market segmentation by Distribution Channel

The Influenza Vaccine Market is experiencing significant growth due to the increasing number of severe influenza cases, particularly among children. The Global Influenza Program continues to prioritize the development of new vaccines, including combination vaccines and mRNA vaccines, to address regional epidemics and reduce deaths from flu cases. Several approved influenza vaccines are available, such as FluLaval Quadrivalent, Fluzone, and Fluad. These vaccines, available at hospitals and pharmacies, come in various forms, including flu shots and nasal spray vaccines. Both inactivated and live attenuated vaccines are used, with quadrivalent and trivalent vaccines available for both pediatric and adult populations. Seasonal influenza vaccines are crucial in preventing the spread of the influenza virus, which causes infectious diseases like swine flu. The availability of vaccine strains that match the current virus strain is essential in ensuring effective immune response. With several new vaccines in Phase III clinical trials, the market for influenza vaccines is expected to continue its high growth trajectory.

Geography Overview

The Influenza Vaccine Market in North America is dominated by severe influenza cases, particularly among children. The Global Influenza Program, spearheaded by organizations like the Pan American Health Organization (PAHO), plays a crucial role in shaping the market through recommended immunization schedules. Combination vaccines, such as BOOSTRIX, INFANRIX, Pediarix, BEXSERO, MENVEO, and influenza, are major contributors to the market. The prevalence of infectious diseases, including influenza, has been increasing significantly in developed countries, with the US experiencing high levels of flu cases from November to February each year. Seasonal influenza vaccines, including inactivated, quadrivalent, trivalent, pediatric, and adult vaccines, are available at hospitals and retail pharmacies. The market also includes mRNA vaccines, such as those used for swine flu and flu shots, which have gained popularity due to their ability to stimulate a strong immune response. Regional epidemics and deaths caused by influenza virus strains continue to drive the demand for vaccines, with vaccine strains updated annually to address seasonal changes. 

Insights on the market contribution of various segments including country and region wise, historic (2017 - 2021) and forecast market size- Download a Sample Report

Insights on Market Drivers, trends, & Challenges, historic period(2017 - 2021) and forecast period(2023-2027)- Request a sample report!

Research Analysis

The Influenza Vaccine Market encompasses various types of vaccines, including inactivated, live attenuated, quadrivalent, trivalent, combination, and mRNA vaccines. These vaccines are essential in mitigating the impact of regional epidemics caused by the Influenza virus. The Global Influenza Program plays a crucial role in monitoring the virus and ensuring the availability of effective vaccine strains. Seasonal influenza vaccines, such as the flu shot and nasal spray vaccines, are administered annually to children and adults to prevent severe influenza cases and related deaths. Hospital & retail pharmacies serve as vital distribution channels for these vaccines. The vaccine market also includes Swine flu vaccines, designed to protect against specific strains of the influenza virus. The immune response generated by these vaccines is crucial in reducing the number of flu cases and associated fatalities. Vaccine manufacturers continually innovate, developing new vaccine strains and delivery methods to improve vaccine efficacy and accessibility. The market for influenza vaccines is dynamic, with ongoing research and development efforts aimed at addressing the evolving nature of the influenza virus.

Market Research Overview

The Influenza Vaccine Market plays a crucial role in preventing seasonal and pandemic influenza cases. The market is driven by the increasing prevalence of influenza, rising awareness about vaccination, and government initiatives to promote immunization. The market comprises various types of influenza vaccines, including trivalent inactivated vaccines (TIVs), live attenuated influenza vaccines (LAIVs), and recombinant influenza vaccines. These vaccines are distributed through various channels, including hospitals, clinics, pharmacies, and government health programs. The market is also influenced by factors such as regulatory requirements, pricing pressures, and competition from other vaccines and treatments. Despite challenges, the Influenza Vaccine Market continues to expand, driven by the need to protect populations from the harmful effects of influenza.

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

These press releases may also interest you

at 17:21
On Tuesday, May 28, the Second Gentleman will deliver remarks at an event to raise awareness about the physical and mental health challenges affecting young people. The Second Gentleman will uplift the Biden-Harris Administration's actions to tackle...

at 17:05
Agenus Inc. ("Agenus") , a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus' Board of Directors granted inducement awards to Eric Olson, in connection...

at 16:46
Vanda Pharmaceuticals Inc. (Vanda) today announced that the Company's Board of Directors (the "Board") carefully reviewed the revised unsolicited proposal from Future Pak, LLC ("FP") to acquire the Company for $7.25 to $7.75 per share in cash plus...

at 16:45
Nutex Health Inc. ("Nutex Health" or the "Company") , a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in nine states and primary care-centric, risk-bearing physician networks,...

at 16:40
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of...

at 16:30
Rakovina Therapeutics Inc. ("Rakovina" or the "Company") announces that in accordance with the terms of an indenture entered into between the Company and Odyssey Trust Company dated May 29, 2023 (the "Indenture"), certain holders (each, a...

News published on and distributed by: